-
2
-
-
0032972089
-
Defining the implant treatment volume for patients with low risk prostate cancer: Does the anterior base need to be treated?
-
D'Amico A.V., Davis A., Vargas S.O., et al. Defining the implant treatment volume for patients with low risk prostate cancer Does the anterior base need to be treated? Int J Radiat Oncol Biol Phys. 43:1999;587-590
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.43
, pp. 587-590
-
-
D'Amico, A.V.1
Davis, A.2
Vargas, S.O.3
-
4
-
-
0034667653
-
Detailed mapping of prostate carcinoma foci: Biopsy strategy implications
-
Chen M.E., Johnston D.A., Tang K., et al. Detailed mapping of prostate carcinoma foci Biopsy strategy implications. Cancer. 89:2000;1800-1809
-
(2000)
Cancer
, vol.89
, pp. 1800-1809
-
-
Chen, M.E.1
Johnston, D.A.2
Tang, K.3
-
7
-
-
0032913909
-
Fractionation and protraction for radiotherapy of prostate carcinoma
-
Brenner D.J., Hall E.J. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys. 43:1999;1095-1101
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.43
, pp. 1095-1101
-
-
Brenner, D.J.1
Hall, E.J.2
-
8
-
-
0036140325
-
Direct evidence that prostate tumours show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue
-
Brenner D.J., Martinez A.A., Edmundson G.K., et al. Direct evidence that prostate tumours show high sensitivity to fractionation (low α/β ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys. 52:2002;6-13
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.52
, pp. 6-13
-
-
Brenner, D.J.1
Martinez, A.A.2
Edmundson, G.K.3
-
10
-
-
0033026882
-
What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy
-
Duchesne G.M., Peters L.J. What is the α/β ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys. 44:1999;747-748
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.44
, pp. 747-748
-
-
Duchesne, G.M.1
Peters, L.J.2
-
12
-
-
0035450897
-
A simple analytic derivation suggests that prostate cancer α/β ratio is low
-
King C.R., Fowler J.F. A simple analytic derivation suggests that prostate cancer α/β ratio is low. Int J Radiat Oncol Biol Phys. 51:2001;213-214
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.51
, pp. 213-214
-
-
King, C.R.1
Fowler, J.F.2
-
13
-
-
0034183792
-
Is the prostate α/β ratio of 1.5 from Brenner & Hall a modelling artefact?
-
King C., Mayo C.S. Is the prostate α/β ratio of 1.5 from Brenner & Hall a modelling artefact? Int J Radiat Oncol Biol Phys. 47:2000;536-538
-
(2000)
Int J Radiat Oncol Biol Phys
, vol.47
, pp. 536-538
-
-
King, C.1
Mayo, C.S.2
-
14
-
-
0037458373
-
The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer
-
Lindsay P.E., Moiseenko V.V., Van Dyk J., Battista J.J. The influence of brachytherapy dose heterogeneity on estimates of α/β for prostate cancer. Phys Med Biol. 48:2003;507-522
-
(2003)
Phys Med Biol
, vol.48
, pp. 507-522
-
-
Lindsay, P.E.1
Moiseenko, V.V.2
Van Dyk, J.3
Battista, J.J.4
-
15
-
-
0042383102
-
How low is the α/β ratio for prostate cancer? in regard to Wang, et al
-
Fowler J.F., Chappell R.J. How low is the α/β ratio for prostate cancer? In regard to Wang, et al. Int J Radiat Oncol Biol Phys. 57:2003;593-595
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.57
, pp. 593-595
-
-
Fowler, J.F.1
Chappell, R.J.2
-
16
-
-
0041381048
-
Low α/β ratio for prostate cancer: In response to Dr Fowler, et al
-
Wang J.Z., Guerrero M., Li X.A. Low α/β ratio for prostate cancer in response to Dr Fowler, et al. Int J Radiat Oncol Biol Phys. 57:2003;595-596
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.57
, pp. 595-596
-
-
Wang, J.Z.1
Guerrero, M.2
Li, X.A.3
-
17
-
-
0034487516
-
Registration of prostate volume with radiographically identified I-125 seeds for permanent implant evaluation
-
Haworth A., Ebert M., Joseph D., Kaye K. Registration of prostate volume with radiographically identified I-125 seeds for permanent implant evaluation. J Brachytherapy Int. 16:2000;157-167
-
(2000)
J Brachytherapy Int
, vol.16
, pp. 157-167
-
-
Haworth, A.1
Ebert, M.2
Joseph, D.3
Kaye, K.4
-
18
-
-
0028919251
-
Dosimetry of interstitial brachytherapy sources: Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43
-
Nath R., Anderson L.L., Luxton G., et al. Dosimetry of interstitial brachytherapy sources Recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. Med Phys. 22:1995;209-234
-
(1995)
Med Phys
, vol.22
, pp. 209-234
-
-
Nath, R.1
Anderson, L.L.2
Luxton, G.3
-
19
-
-
0034089299
-
Modelling dose-response in the presence of spatial variations in dose-rate
-
Ebert M., Zavgorodni S. Modelling dose-response in the presence of spatial variations in dose-rate. Med Phys. 27:2000;393-400
-
(2000)
Med Phys
, vol.27
, pp. 393-400
-
-
Ebert, M.1
Zavgorodni, S.2
-
20
-
-
0029763734
-
Dose rate effects in targeted radiotherapy
-
Dale R.G. Dose rate effects in targeted radiotherapy. Phys Med Biol. 41:1996;1871-1884
-
(1996)
Phys Med Biol
, vol.41
, pp. 1871-1884
-
-
Dale, R.G.1
-
21
-
-
0027223126
-
A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density
-
Webb S., Nahum A.E. A model for calculating tumour control probability in radiotherapy including the effects of inhomogeneous distributions of dose and clonogenic cell density. Phys Med Biol. 38:1993;653-666
-
(1993)
Phys Med Biol
, vol.38
, pp. 653-666
-
-
Webb, S.1
Nahum, A.E.2
-
22
-
-
0028073266
-
Optimum parameters in a model for tumour control probability including interpatient heterogeneity
-
Webb S. Optimum parameters in a model for tumour control probability including interpatient heterogeneity. Phys Med Biol. 39:1994;1895-1914
-
(1994)
Phys Med Biol
, vol.39
, pp. 1895-1914
-
-
Webb, S.1
-
23
-
-
0042884208
-
Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: Implications for the α/β ratio
-
Nahum A.E., Movsas B., Horwitz E.M., et al. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer Implications for the α/β ratio. Int J Radiat Oncol Biol Phys. 57:2003;391-401
-
(2003)
Int J Radiat Oncol Biol Phys
, vol.57
, pp. 391-401
-
-
Nahum, A.E.1
Movsas, B.2
Horwitz, E.M.3
-
24
-
-
0036471914
-
Prostate brachytherapy postimplant dosimetry: A comparison of prostate quadrants
-
Sidhu S., Morris W.J., Spadinger I., et al. Prostate brachytherapy postimplant dosimetry a comparison of prostate quadrants. Int J Radiat Oncol Biol Phys. 52:2002;544-552
-
(2002)
Int J Radiat Oncol Biol Phys
, vol.52
, pp. 544-552
-
-
Sidhu, S.1
Morris, W.J.2
Spadinger, I.3
-
26
-
-
0035889359
-
Fitting of tumour control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer: Pitfalls in deducing radiobiological parameters for tumours from clinical data
-
Levegrun S., Jackson A., Zelefsky M.J., et al. Fitting of tumour control probability models to biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer pitfalls in deducing radiobiological parameters for tumours from clinical data. Int J Radiat Oncol Biol Phys. 4:2001;1064-1080
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.4
, pp. 1064-1080
-
-
Levegrun, S.1
Jackson, A.2
Zelefsky, M.J.3
-
27
-
-
0032912743
-
The delta-TCP concept: A clinically useful measure of tumour control probability
-
Sanchez-Nieto B., Nahum A.E. The delta-TCP concept A clinically useful measure of tumour control probability. Int J Radiat Oncol Biol Phys. 44:1999;369-380
-
(1999)
Int J Radiat Oncol Biol Phys
, vol.44
, pp. 369-380
-
-
Sanchez-Nieto, B.1
Nahum, A.E.2
-
28
-
-
0032588023
-
Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
-
Zelefsky M.J., Wallner K.E., Ling C.C., et al. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer. J. Clin Oncol. 17:1999;517-522
-
(1999)
J. Clin Oncol
, vol.17
, pp. 517-522
-
-
Zelefsky, M.J.1
Wallner, K.E.2
Ling, C.C.3
|